Danaher Co. (NYSE:DHR) Holdings Raised by Capital Analysts LLC

Capital Analysts LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 20.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,801 shares of the conglomerate’s stock after purchasing an additional 2,205 shares during the period. Capital Analysts LLC’s holdings in Danaher were worth $2,961,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. DHJJ Financial Advisors Ltd. purchased a new stake in shares of Danaher during the third quarter valued at $25,000. BKM Wealth Management LLC purchased a new stake in shares of Danaher during the fourth quarter valued at $27,000. OFI Invest Asset Management purchased a new stake in shares of Danaher during the third quarter valued at $30,000. First Capital Advisors Group LLC. purchased a new stake in Danaher in the 2nd quarter worth about $32,000. Finally, BOK Financial Private Wealth Inc. purchased a new stake in Danaher in the 3rd quarter worth about $34,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup increased their price objective on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. increased their price objective on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Barclays raised their price objective on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada raised their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $267.43.

Insiders Place Their Bets

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,957 shares of company stock worth $8,265,802. Corporate insiders own 10.90% of the company’s stock.

Danaher Stock Up 0.2 %

Shares of Danaher stock opened at $240.02 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The business has a fifty day simple moving average of $249.58 and a 200 day simple moving average of $229.84. The stock has a market cap of $177.74 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the previous year, the firm earned $2.87 earnings per share. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. Research analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.